Sunday, March 10, 2024

 

Brain waves travel in one direction when memories are made and the opposite when recalled


Peer-Reviewed Publication

COLUMBIA UNIVERSITY SCHOOL OF ENGINEERING AND APPLIED SCIENCE

Brain 

IMAGE: 

TRAVELING WAVE PROPAGATION DIRECTIONS IN THE MEMORY TASK REVEAL HOW THE BRAIN QUICKLY COORDINATES ACTIVITY AND SHARES INFORMATION ACROSS MULTIPLE REGIONS

view more 

CREDIT: HONGHUI ZHANG




In the space of just a few seconds, a person walking down a city block might check their phone, yawn, worry about making rent, and adjust their path to avoid a puddle. The smell from a food cart could suddenly conjure a memory from childhood, or they could notice a rat eating a slice of pizza and store the image as a new memory. 

 

For most people, shifting through behaviors quickly and seamlessly is a mundane part of everyday life. 

 

For neuroscientists, it’s one of the brain’s most remarkable capabilities. That’s because different activities require the brain to use different combinations of its many regions and billions of neurons. How it manages to do this so rapidly has been an open question for decades. 

 

The Study

In a paper published March 8 in Nature Human Behaviour, a team of researchers, led by Joshua Jacobs, associate professor of biomedical engineering at Columbia Engineering, shed new light on this question. By carefully monitoring neural activity of people who were recalling memories or forming new ones, the researchers managed to detect how a newly appreciated type of brainwave — traveling waves — influences the storage and retrieval of memories. 

 

“Broadly, we found that waves tended to move from the back of the brain to the front while patients were putting something into their memory,” said the paper’s co-author Uma R. Mohan, a postdoctoral researcher at NIH and former postdoctoral researcher in the Electrophysiology, Memory, and Navigation Laboratory at Columbia Engineering. “When patients were later searching to recall the same information, those waves moved in the opposite direction, from the front towards the back of the brain,” she said. 

 

In the brains of some of the study’s 93 participants, waves traveled in other directions. 

 

“There was a lot of diversity across patients, so we implemented a framework based on the direction an individual’s oscillations ‘preferred’ to travel,” Mohan said.

 

The researchers say these findings advance fundamental neuroscience research and point toward diagnostic and therapeutic approaches for memory-related disorders.

 

“We think the work may lead to new approaches for interfacing with the brain. By measuring the direction that a person’s brain waves move, we may be able to predict their behavior,” Jacobs said.


 

The Challenge

Brain waves are patterns of electrical oscillations that reflect the state of hundreds or thousands of individual neurons at a particular moment. One major question, which remains unsettled, is whether brain waves drive activity or simply occur as a byproduct of neural activity that was already happening. Researchers who study brain waves have tended to treat them as a stationary phenomenon that occurs in a particular region, noting when oscillations in multiple regions seem synchronized.

 

In this study, Mohan and her colleagues contribute to a growing understanding of these oscillations differently, as “traveling waves” that spread across the brain’s cortex, the outermost layer that supports higher cognitive processing. Mohan compares the traveling waves to the ripples that would spread outward after a pebble was thrown into a pond. 

 

“We're looking at neural oscillations not as independent stationary things but as things that are constantly and spontaneously moving across the brain in a dynamic way,” Mohan said.

 

This relatively new way of understanding brain waves is an exciting step in neuroscience because it offers a pathway to explaining how the brain quickly coordinates activity and shares information across multiple regions.

 

The Experiments and Results

This study drew on data from participants who were being treated for drug-resistant epilepsy at hospitals across the United States. The experiments occurred while the participants had grids or strips of electrodes temporarily implanted on the surface of the brain, beneath the skull, to determine where the patients’ seizures arise. For the researchers, these electrodes offer the chance to perform experiments that wouldn’t otherwise be feasible. 

 

“It’s a rare opportunity to be able to see what's going on directly from the brain while the participants are engaged in different cognitive behaviors,” Mohan said.

 

During the experiments, researchers recorded the participants’ brain activity while they performed tasks that required memorizing and recalling lists of words or letters.

 

After the experiments, the researchers analyzed the brain activity from each participant in the context of what they were doing in the memory task and how well they performed. 

 

“I implemented a method to label waves traveling in one direction as basically ‘good for putting something into memory.’ Then we could see how the direction switched over the course of the task,” Mohan said. This method builds on previous research from the Jacobs lab by expanding the mathematical framework used to make sense of the vast quantities of data these experiments produced.

 

“The waves tended to go in the participant’s encoding direction when that participant was putting something into memory and in the opposite direction right before they recalled the word,” she said. “ Overall, this new work links traveling waves to behavior by demonstrating that traveling waves propagate in different directions across the cortex for separate memory processes.”

 

The data also showed that participants tended to perform the memory task more accurately when the traveling waves were moving in the appropriate direction for memory storage and recall. 

 

“These findings shed light on the mechanisms that underlie memory processing. More broadly, they help us better understand how the brain supports a wide range of behaviors that involve precisely coordinated interactions between brain regions,” Mohan said.

 

Potential Impact and Future Directions

As traveling waves are increasingly well understood, they could be the basis for a new class of diagnostic tools that recognize abnormal patterns in brain activity. 

 

There is also significant therapeutic potential. 

 

“If someone’s waves are moving in the wrong direction when they're about to try to remember something, that might put them in a poor memory state,” Mohan explained. “If you could apply stimulation in the right way, you could maybe push those waves to move in a different direction, bringing about a fundamentally different memory state.”

 

Advances in understanding traveling waves offer significant potential for human-computer interaction.

 

In terms of both research and application, Mohan notes that memory is just the starting point.

 

“I am interested in how characteristics of cortical traveling waves change to support a wide range of cognitive functions, including attention and associative memory,” she said.

 

“The direction of traveling wave propagation may tell us where information is moving across the brain at each moment, showing us how different parts of the brain transfer information during behavior,” Jacobs said.

 

Innovative open research publisher PeerJ joins Taylor & Francis


Business Announcement

TAYLOR & FRANCIS GROUP




Leading research publisher Taylor & Francis has announced the addition of PeerJ, a pioneer in broad-scope open access (OA) journals.

PeerJ is best known for its multidisciplinary flagship title PeerJ Life & Environment serving the Biological, Medical and Environmental Sciences and PeerJ Computer Science (covering all areas of computer science, including AI, quantum, and robotics). In addition, PeerJ offers five titles in the Chemical Sciences, meaning that in total Taylor & Francis will welcome seven new journals to its open research program.

All PeerJ journals offer high-quality peer review and rapid publication, supported by PeerJ’s own submission and peer review platform, and dedicated contributor support. Articles are selected on scientific value and methodological soundness, providing a forum for world-class research addressing many of the globe’s current challenges. PeerJ also hosts a digital hub for the International Association for Biological Oceanography, promoting the advancement of knowledge of the biology of the sea.

Joining Taylor & Francis will enable PeerJ to expand its offering to researchers, including participation in Taylor & Francis’ popular manuscript transfer service, and will give scope to extend into new disciplines. PeerJ and Taylor & Francis have complementary publishing programs, with shared commitments to prioritize research integrity, empower knowledge-makers and advance open research.

Leon Heward-Mills, Researcher Services Managing Director at Taylor & Francis, said: “Taylor & Francis has a strong track record of investing in well-respected open research publishers, such as F1000 and Dove Press, and supporting them to develop and innovate at greater scale.”

Heward-Mills added: “We’re delighted that PeerJ’s founders, Peter Binfield and Jason Hoyt, and their team will be joining us. We look forward to learning from their unique insights and experience in open research.”

“Becoming part of Taylor & Francis is an important step in PeerJ’s evolution,” explained Peter Binfield, PeerJ Co-Founder and Publisher. “This move will allow us to cement our original commitments to open research, equitable and inclusive publishing and rigorous peer review. Above all, our commitment to the communities that have supported our journey so far remains unchanged.”

Jason Hoyt, PeerJ Co-Founder and CEO added: “Our mission to make scientific research accessible to all whilst delivering 21st century technology aligns perfectly with Taylor & Francis’ vision. With their backing and global network, we can bring our ethos and approach to even more researchers and readers worldwide. We look forward to introducing new communities to PeerJ.”

 

Deciphering catalysts: Unveiling structure-activity correlations


Peer-Reviewed Publication

ADVANCED INSTITUTE FOR MATERIALS RESEARCH (AIMR), TOHOKU UNIVERSITY

Figure 1 

IMAGE: 

THE STANDARD RESEARCH PARADIGM UNCOVERS THE STRUCTURE-PROPERTY-ACTIVITY RELATIONSHIPS FOR THE ELECTROCHEMICAL CO2 REDUCTION REACTION (CO2RR) OVER SNO2. THIS PICTURE ILLUSTRATES THE SURFACE RECONSTRUCTION INDUCED BY OXYGEN VACANCIES (1/1 ML COVERAGE) AND SURFACE-ACTIVE SPECIES (SN LAYER) ACCOUNTABLE FOR SELECTIVE HCOOH PRODUCTION.

view more 

CREDIT: HAO LI ET AL.




In a new step towards combating climate change and transitioning to sustainable solutions, a group of researchers has developed a research paradigm that makes it easier to decipher the relationship between catalyst structures and their reactions.

Details of the researchers' breakthrough were published in the journal Angewandte Chemie on January 29, 2024.

Understanding how a catalyst's surface affects its activity can aid the design of efficient catalyst structures for specific reactivity requirements. However, grasping the mechanisms behind this relationship is no straightforward task given the complicated interface microenvironment of electrocatalysts.

"To decipher this, we honed in on the electrochemical CO2 reduction reaction (CO2RR) in Tin-Oxide-based (Sn-O) catalysts," points out Hao Li, associate professor at Tohoku University's Advanced Institute for Materials Research (WPI-AIMR) and corresponding author of the paper. "In doing so, we not only uncovered the active surface species of SnO2-based catalysts during CO2RR but also established a clear correlation between surface speciation and CO2RR performance."

CO2RR is recognized as a promising method for reducing CO2 emissions and producing high-value fuels, with formic acid (HCOOH) being a noteworthy product because of its various applications in industries such as pharmaceuticals, metallurgy, and environmental remediation.

The proposed method helped identify the genuine surface states of SnO2 responsible for its performance in CO2 reduction reactions under specific electrocatalytic conditions. Moreover, the team corroborated their findings through experiments using various SnO2 shapes and advanced characterization techniques.

Li and his colleagues developed their methodology by combining theoretical studies with experimental electrochemical techniques.

"We bridged the gap between the theoretical and experimental, offering a comprehensive understanding of catalyst behavior under real-world conditions in the process," adds Li.

The research team is now focused on applying this methodology to a variety of electrochemical reactions. In doing those, they hope to uncover more about unique structure-activity correlations, accelerating the design of high-performance and scalable electrocatalysts.

About the World Premier International Research Center Initiative (WPI)

The WPI program was launched in 2007 by Japan's Ministry of Education, Culture, Sports, Science and Technology (MEXT) to foster globally visible research centers boasting the highest standards and outstanding research environments. Numbering more than a dozen and operating at institutions throughout the country, these centers are given a high degree of autonomy, allowing them to engage in innovative modes of management and research. The program is administered by the Japan Society for the Promotion of Science (JSPS).

See the latest research news from the centers at the WPI News Portal: https://www.eurekalert.org/newsportal/WPI
Main WPI program site:  www.jsps.go.jp/english/e-toplevel

Advanced Institute for Materials Research (AIMR)
Tohoku University

Establish a World-Leading Research Center for Materials Science
AIMR aims to contribute to society through its actions as a world-leading research center for materials science and push the boundaries of research frontiers. To this end, the institute gathers excellent researchers in the fields of physics, chemistry, materials science, engineering, and mathematics and provides a world-class research environment.
 

Disclaimer: AAAS and EurekAlert! are not re

 

Duke-NUS research discovery sparks hope: Zika virus vaccine emerges as an unlikely hero in battling brain cancer

• The scientists discovered that Zika virus vaccine strains eradicate brain tumour cells while sparing healthy ones

Peer-Reviewed Publication

DUKE-NUS MEDICAL SCHOOL

Research Team 

IMAGE: 

FROM RIGHT, ASSISTANT PROFESSOR ANN-MARIE CHACKO, ASSISTANT PROFESSOR ALFRED SUN, DR CARLA BIANCA LUENA VICTORIO AND PROFESSOR OOI ENG EONG WITH A CULTURE OF THEIR ZIKA VACCINE STRAINS

view more 

CREDIT: DUKE-NUS MEDICAL SCHOOL

Scientists from Duke-NUS Medical School (Duke-NUS) have developed a new approach using the Zika virus to destroy brain cancer cells and inhibit tumour growth, while sparing healthy cells. Using Zika virus vaccine candidates developed at Duke-NUS, the team discovered how these strains target rapidly proliferating cells over mature cells—making them an ideal option to target fast-growing cancerous cells in the adult brain. Their findings, published in the Journal of Translational Medicine, potentially offer a new treatment alternative for brain cancer patients who currently have a poor prognosis.

Glioblastoma multiforme is the most common malignant brain cancer, with more than 300,000 patients diagnosed annually worldwide[i]. Survival rates for such patients are poor (around 15 months), mainly due to high incidence of tumour recurrence and limited treatment options. For such patients, oncolytic virotherapy—or the use of engineered viruses to infect and kill cancer cells—may address the current therapeutic challenges.

Zika virus is one such option in early development. The Duke-NUS team used Zika virus live-attenuated vaccine (ZIKV-LAV) strains, which are “weakened” viruses with limited ability to infect healthy cells but can still grow rapidly and spread within a tumour mass.

“We selected Zika virus because it naturally infects rapidly multiplying cells in the brain, allowing us to reach cancer cells that are traditionally difficult to target. Our ZIKV-LAV strains also replicate themselves in brain cancer cells, making this a living therapy that can spread and attack neighbouring diseased cells,” said Dr Carla Bianca Luena Victorio, first author of the paper and Senior Research Fellow at the Cancer & Stem Cell Biology Research Programme at Duke-NUS.

Dr Victorio and the team determined that ZIKV-LAV strains were highly effective in infecting cancer cells as these viruses bind to proteins that are present in high levels only in cancer cells and not in healthy cells. Upon infecting a cancer cell, these virus strains hijack the cell’s resources to reproduce, ultimately killing the cell. As the cancer cell’s protective membrane ruptures upon death, it releases its contents, including virus progeny that can infect and kill neighbouring cancer cells. In addition, some cellular proteins released from the infected cells  can activate an immune response to further inhibit tumour growth.

Through their experiments, the team observed that infection from ZIKV-LAV strains caused 65 to 90 per cent of glioblastoma multiforme tumour cells to die. While the ZIKV-LAV strains also infected 9 to 20 per cent of cells from blood vessels in the brain, the infection did not kill these healthy cells. In contrast, the original parent Zika virus strain killed up to 50 per cent of healthy brain cells.

The scientists also discovered that the ZIKV-LAV strains were not able to reproduce well even when they managed to infect healthy cells. The amount of virus measured in healthy brain cells infected with ZIKV-LAV was only 0.36 to 9 times higher than before infection. In contrast, the amount of virus in brain cancer cells infected with ZIKV-LAV was 100 to a billion times higher than before infection. This further illustrates that conditions in cancer cells are significantly more conducive for virus reproduction than in normal cells.

“Since the Zika virus outbreak in 2016, understandably, there has been fear about the nature of the virus and its devastating effects. Through our work, we hope to present the Zika virus in a new light by highlighting its potential to kill cancer cells. When a live virus is attenuated, such that it is safe and effective to fight infectious diseases, it can be beneficial to human health—not just as a vaccine but also as a potent tumour-eradicating agent,” said Assistant Professor Ann-Marie Chacko from Duke-NUS’ Cancer & Stem Cell Biology Research Programme. She is also the senior author of the paper.

The live attenuated virus strains were originally developed as a vaccine by Professor Ooi Eng Eong's group from Duke-NUS’ Emerging Infectious Diseases Research Programme. As a control, the virus strains were also tested on brain neurons or nerve cells that had been cultivated from human stem cells by Assistant Professor Alfred Sun’s team from the Neuroscience & Behavioural Disorders Research Programme in Duke-NUS. This provides a reliable screening tool to assess the safety and efficacy of using the virus as therapy in human cells.  

Asst Prof Chacko’s group is improving these and other Zika virus strains to increase their potency in killing not only brain cancer cells, but other types of cancer cells as well, while making them safer for use in patients. They are also modifying the virus so it can be imaged non-invasively after it has been injected into a patient. This will allow doctors to monitor where the virus goes in the patient and how long it is functional in the tumour.

To this end, the group is exploring commercialising their virus strains as both a Zika vaccine and treatment for brain cancer, and potentially other cancers, such as ovarian cancer.

Professor Patrick Tan, Senior Vice-Dean for Research at Duke-NUS, said: “This is a sterling example of how different research programmes within the School come together to tap their various expertise to advance medical knowledge and improve patients’ lives. The team’s valuable insights may one day translate into a new treatment option to control tumour growth or even, offer a cure for cancer.”

 

###

 

Reference: Victorio, C.B. et al. (2024) ‘Repurposing of zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells’, Journal of Translational Medicine, 22(1). doi:10.1186/s12967-024-04930-4.

 

 


[i] Fan, Y., Zhang, X., Gao, C. et al. Burden and trends of brain and central nervous system cancer from 1990 to 2019 at the global, regional, and country levels. Arch Public Health 80, 209 (2022). https://doi.org/10.1186/s13690-022-00965-5.

 

About Duke-NUS Medical School                    

Duke-NUS is Singapore’s flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted ‘Clinicians Plus’ poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore’s largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.   

For more information, please visit www.duke-nus.edu.sg 

  

Cultured human neurons infected with ZIKV-LAV. Infection in pink and cell nuclei in blue.

CREDIT

Duke-NUS Medical School

 

Researchers develop artificial building blocks of life


Peer-Reviewed Publication

UNIVERSITY OF COLOGNE

Artificial nukleotides 

IMAGE: 

STRUCTURAL COMPARISON OF DNA AND THE ARTIFICIAL TNA, A XENO NUCLEIC ACID WITH THE NATURAL BASE PAIRS AT AND GC AND AN ADDITIONAL BASE PAIR (XY).

view more 

CREDIT: STEPHANIE KATH-SCHORR




The DNA carries the genetic information of all living organisms and consists of only four different building blocks, the nucleotides. Nucleotides are composed of three distinctive parts: a sugar molecule, a phosphate group and one of the four nucleobases adenine, thymine, guanine and cytosine. The nucleotides are lined up millions of times and form the DNA double helix, similar to a spiral staircase. Scientists from the UoC’s Department of Chemistry have now shown that the structure of nucleotides can be modified to a great extent in the laboratory. The researchers developed so-called threofuranosyl nucleic acid (TNA) with a new, additional base pair. These are the first steps on the way to fully artificial nucleic acids with enhanced chemical functionalities. The study ‘Expanding the Horizon of the Xeno Nucleic Acid Space: Threose Nucleic Acids with Increased Information Storage’ was published in the Journal of the American Chemical Society.

Artificial nucleic acids differ in structure from their originals. These changes affect their stability and function. “Our threofuranosyl nucleic acid is more stable than the naturally occurring nucleic acids DNA and RNA, which brings many advantages for future therapeutic use,” said Professor Dr Stephanie Kath-Schorr. For the study, the 5-carbon sugar deoxyribose, which forms the backbone in DNA, was replaced by a 4-carbon sugar. In addition, the number of nucleobases was increased from four to six. By exchanging the sugar, the TNA is not recognized by the cell's own degradation enzymes. This has been a problem with nucleic acid-based therapeutics, as synthetically produced RNA that is introduced into a cell is rapidly degraded and loses its effect. The introduction of TNAs into cells that remain undetected could now maintain the effect for longer.  “In addition, the built-in unnatural base pair enables alternative binding options to target molecules in the cell,” added Hannah Depmeier, lead author of the study.  Kath-Schorr is certain that such a function can be used in particular in the development of new aptamers, short DNA or RNA sequences, which can be used for the targeted control of cellular mechanisms. TNAs could also be used for the targeted transport of drugs to specific organs in the body (targeted drug delivery) as well as in diagnostics; they could also be useful for the recognition of viral proteins or biomarkers.

 

U-M researchers open new leads in anti-HIV drug development, using a compound found in nature


Peer-Reviewed Publication

UNIVERSITY OF MICHIGAN




A team of University of Michigan researchers has successfully modified a naturally occurring chemical compound in the lab, resulting in advanced lead compounds with anti-HIV activity.

 

Their results, published March 7 in the Journal of Medicinal Chemistry, offer a new path forward in the development of drugs that could potentially help cure—rather than treat—HIV.

 

Although effective treatments are available to manage HIV, a cure has remained elusive due to the virus's ability to hide from the immune system, lying dormant in reservoirs of infected cells.

 

"With most viruses, when people get infected, they get sick for a while and then the immune system kicks in and the virus is cleared," said Kathleen Collins, professor of microbiology and immunology at the U-M Medical School. "But with HIV, once a patient is infected, that virus will persist for their entire life—meaning they must remain on treatments indefinitely."

 

One key to HIV's ability to remain hidden in patients' cells is a protein that the virus makes, called Nef. This protein shuts down a system that the cell would normally use to alert the immune system to an infection, thus preventing the immune cells from recognizing and clearing the virus.

 

Collins and her lab have studied this protein for more than 15 years, investigating how it works and how it can be disabled. She and David Sherman, professor at the U-M Life Sciences Institute, previously discovered that a chemical found in nature can inhibit HIV Nef, allowing the immune system to find and eliminate virally infected cells: a compound called concanamycin A (CMA), which is produced by a soil-derived microorganism.

 

In its natural form, however, CMA presents several challenges as a potential therapeutic. The first challenge the team had to overcome was supply. While CMA is a naturally occurring compound, the original bacteria that produces it does so in quantities far too small to be useful for testing and modification in the lab.

 

Another major challenge with developing CMA as an anti-HIV drug is that Nef is not CMA's primary target.

 

"CMA's main job in human cells is to inhibit an enzyme called V-ATPase, which we absolutely do not want to block in this case," said Sherman, who is also a professor at the U-M College of Pharmacy, Medical School, and College of Literature, Science, and the Arts. "So, we needed to find a way to modify CMA's activity, widening the effective dosage gap between when it starts to inhibit the target we're aiming for—HIV Nef — without affecting V-ATPase, its typical cellular target."

 

With this latest research, the team has overcome both of these challenges. Using bioengineering, Sherman's team was able to develop a bacterial strain that increased CMA production 2,000-fold. Synthetic chemists in the lab then created more than 70 new variations of the compound, swapping out different chemical groups, to test for their potency against HIV Nef.

 

Collins' lab team ran the new compounds through a battery of tests to measure their toxicity to cells, as well as how they affected the activities of both HIV Nef and V-ATPase.

 

"Even though we know that CMA is extremely active against the HIV Nef protein, all drugs have side effects," said Collins, also a professor of internal medicine at the Medical School. "And so we wanted to ensure we've done everything we can to minimize the side effect profile of the drug before we consider putting it into an animal or human."

 

The team now has several CMA analogs that show high potency in blocking HIV Nef at very low dosage levels, without interrupting off-target effects or causing toxicity in human cells. They caution, however, that several important steps remain before the compounds would be ready for further testing in a clinical setting.

 

"We are really encouraged, though, because our groups have solved some very important problems," Sherman said. "We have engineered microorganisms to produce sustainable supplies of the natural product molecules and have really good chemical methods to make new analogs. And we have the methodologies in place to continue tracking the critical toxicity and potency parameters to further reduce off-target effects."

 

The research was supported by the National Institutes of Health.

 

Other study authors are: Morgan McCauley, Matthew Huston, Alanna Condren, Filipa Pereira, Joel Cline, Marianne Yaple-Maresh, Mark Painter, Gretchen Zimmerman, Andrew Robertson, Nolan Carney, Christopher Goodall and Valeri Terry of U-M and Rolf Müller of Hemholtz Institute for Pharmaceutical Research, Germany.

 

Study: Structure-activity relationships of natural and semisynthetic plecomacrolides suggest distinct pathways for HIV-1 immune evasion and vacuolar ATPase-dependent lysosomal acidification (DOI: 10.1021/acs.jmedchem.3c01574)

 

Written by Emily Kagey, U-M Life Sciences Institute

 

 

Socially prescribed creative play boosts parents’ and children’s wellbeing


Peer-Reviewed Publication

UNIVERSITY OF LEEDS





University of Leeds news 

For immediate release 

Socially prescribed creative play boosts parents’ and children’s wellbeing 

Socially prescribed creative play helps children and their parents develop new skills and promotes wellbeing, a new study has found. 

The University of Leeds-led study evaluated a five-week programme of arts-based play, including singing and music-making, for families of children aged up to three. It found that parents benefited from developing social networks and sharing experiences with each other, as well as learning creative approaches to parenting. The families also gained vital information about their child’s developmental milestones. 

The programme, which was developed by leading children’s arts charity Theatre Hullabaloo to address concerns about parental wellbeing following the pandemic, is the first known socially prescribed creative play intervention for families with children of this age.  

Social prescription is an approach enabling health professionals to refer people in need of help to address their health and wellbeing for non-medical support like local group activities. It can be an effective alternative to medication or other interventions. 

Study author Dr Paige E. Davis, Lecturer in Developmental Psychology in the University of Leeds’ School of Psychology, said: “Social prescription is usually thought to be focused on older and elderly individuals. Recently there has been a push to facilitate different life transitions through social prescription. The transition to parenthood has been neglected in the past in terms of support offered, despite the importance of the relationship between parent and child in the first 1,001 days.” 

“Our study shows that social prescribing for parents and children has benefits for both. Parents believe it improves their wellbeing, while giving them opportunities to build social networks and learn new ways to play creatively. Parents also perceive that it improves their children’s ability to develop new skills.” 

Miranda Thain, Artistic Producer at Theatre Hullabaloo, said: “We see the positive effects of playing creatively with your little one and feeling confident to use those skills in your parenting - whether it be reading, singing or music making - in our work with families every day. Social prescription provides an important route for families who might need extra support and care to take part in programmes of this type.  

“This research, which demonstrates the value in terms of the wellbeing of both parent and child, is hugely important as we make the case for better investment in early years creativity, giving families the tools to be the best they can be for each other.” 

The programme consisted of a one-hour session which had a clear, yet flexible structure. Activities included sensory and imaginary play installations, play stations with age-appropriate toys, books and sensory activities, and more structured ‘Sing and Play’ sessions followed by ‘independent creative play’ time, where children played together while their parents were offered a hot drink. Each session culminated with gentle live music played on the flute and ukulele, sensory lights, bubbles, lullabies and a goodbye song.  

Parents noted key differences between the sessions and typical play groups, which they said could be chaotic and overwhelming. The same group of people attended the study sessions week on week, which parents said was better for developing new connections than typical playgroups, which are open to one-off drop-ins. 

Especially important to parents was their trust in the prescribers and organisation, and the sense of calm that the intervention fostered, because this enabled them to be receptive to practical parenting knowledge and new social relationships.  

Parents believed that the socially prescribed creative play positively impacted their children’s development and their own mental health and knowledge. 

Further research is needed to evaluate the longer-term impact on children’s development and the interactions between parents and their children, the authors say. 

Further information 

My Favourite Part was Learning Different ways to Play; Evaluating a Socially Prescribed Creative Play Programme” is published in Public Health journal on 8 March 2023. 

Email University of Leeds press officer Lauren Ballinger on l.ballinger@leeds.ac.uk with media enquiries. 

University of Leeds  

The University of Leeds is one of the largest higher education institutions in the UK, with more than 38,000 students from more than 150 different countries. We are renowned globally for the quality of our teaching and research.  

We are a values-driven university, and we harness our expertise in research and education to help shape a better future for humanity, working through collaboration to tackle inequalities, achieve societal impact and drive change.   

The University is a member of the Russell Group of research-intensive universities, and plays a significant role in the Turing, Rosalind Franklin and Royce Institutes. www.leeds.ac.uk   

Follow University of Leeds or tag us in to coverage: Twitter | Facebook | LinkedIn | Instagram